Eli Lilly's Surprising Lung Cancer Success Story

Oncology is one of the fastest-growing segments of drug development and, given the needs of cancer sufferers that aren't met, that's good news. It's also good business. Cancer-fighting drugs did an estimated $75 billion in global sales last year.

With that in mind, this episode of The Motley Fool's Market Checkup tackles the biggest news stories of the week involving cancer drugs, and the companies that make them. Watch and find out the latest on a potential biotech buyout, and which big pharma stock got a surprising result in late-stage trials.

In this video, health-care analysts David Williamson and Max Macaluso discuss Eli Lilly's recent pipeline success, which caught investors off guard. Find out why this lung cancer drug surprised in phase 3 trials, why the positive news couldn't have come at a better time, and how much investors should be excited as it moves into the FDA review process.

One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report, "Secure Your Future With 9 Rock-Solid Dividend Stocks," outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Follow David on Twitter: @MotleyDavid.

The article Eli Lilly's Surprising Lung Cancer Success Story originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.